Luis Andrés Padró Alonzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luis Andrés Padró Alonzo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrés Rivera Reséndiz
Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Norte, Huixquilucan 52786, Mexico
1 shared publication - Diego-Abelardo Álvarez-Hernández
Carlos Slim Foundation, Mexico City, Mexico
1 shared publication - Eunice Nabil Vega López
Medical IMPACT, Infectious Diseases Department, Mexico City 53900, Mexico
1 shared publication - Giorgio Franyuti
Medical IMPACT, Infectious Diseases Department, Mexico City 53900, Mexico
1 shared publication - Jorge Andrés Abello Vaamonde
Department of Radiology, Mayo Clinic, Jacksonville FL
1 shared publication - Jorge Ernesto Juárez Bañuelos
Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Norte, Huixquilucan 52786, Mexico
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 23 April 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (4) , 205
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
Acinetobacter baumannii (named in honor of the American bacteriologists Paul and Linda Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial infections, especially in intensive care units (ICUs) and immunocompromised patients with central venous catheters. A. baumannii has developed a broad spectrum of antimicrobial resistance, associated with a higher mortality rate among infected patients compared with other non-baumannii species. In terms of clinical impact, resistant strains are associated with increases in both in-hospital length of stay and mortality. A. baumannii can cause a variety of infections; most involve the respiratory tract, especially ventilator-associated pneumonia, but bacteremia and skin wound infections have also been reported, the latter of which has been prominently observed in the context of war-related trauma. Cases of meningitis associated with A. baumannii have been documented. The most common risk factor for the acquisition of MDR A baumannii is previous antibiotic use, following by mechanical ventilation, length of ICU/hospital stay, severity of illness, and use of medical devices. Current efforts focus on addressing all the antimicrobial resistance mechanisms described in A. baumannii, with the objective of identifying the most promising therapeutic scheme. Bacteriophage- and artilysin-based therapeutic approaches have been described as effective, but further research into their clinical use is required
- 23 April 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (4) , 205
Top Cited PapersOpen AccessAcinetobacter baumannii Resistance: A Real Challenge for Clinicians
Acinetobacter baumannii (named in honor of the American bacteriologists Paul and Linda Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial infections, especially in intensive care units (ICUs) and immunocompromised patients with central venous catheters. A. baumannii has developed a broad spectrum of antimicrobial resistance, associated with a higher mortality rate among infected patients compared with other non-baumannii species. In terms of clinical impact, resistant strains are associated with increases in both in-hospital length of stay and mortality. A. baumannii can cause a variety of infections; most involve the respiratory tract, especially ventilator-associated pneumonia, but bacteremia and skin wound infections have also been reported, the latter of which has been prominently observed in the context of war-related trauma. Cases of meningitis associated with A. baumannii have been documented. The most common risk factor for the acquisition of MDR A baumannii is previous antibiotic use, following by mechanical ventilation, length of ICU/hospital stay, severity of illness, and use of medical devices. Current efforts focus on addressing all the antimicrobial resistance mechanisms described in A. baumannii, with the objective of identifying the most promising therapeutic scheme. Bacteriophage- and artilysin-based therapeutic approaches have been described as effective, but further research into their clinical use is required